Combined phacoemulsification and YAG-laser activation of trabecula in primary open-angle glaucoma and co-existing cataract
Session Details
Session Title: Presented Poster Session: Combined Cataract Surgery & Cataract Surgery Complications
Venue: Poster Village: Pod 1
First Author: : T.Sokolovskaya RUSSIA
Co Author(s): : D. Magaramov V. Yashina V. Teplovodskaya
Abstract Details
Purpose:
To compare phacoemulsification alone and phacoemulsification with YAG-laser activation of trabecula (YAG-LAT) in eyes with primary open-angle glaucoma.
Setting:
The S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia
Methods:
The study included 65 patients (68 eyes) with initial and advanced stages of primary open-angle glaucoma and complicated cataract. The follow-up period is 12 months after the treatment. The patients were divided into two groups: the main one - 33 patients (36 eyes) who underwent YAG-LAT and phacoemulsification (combined group), and 32 patients (32 eyes) for the control group who underwent phacoemulsification alone.The baseline IOP (P0) in the combined and control groups was 20.8±3.67 mm Hg and 20.23±5.73 mm Hg respectively. The mean medication use was 1.52±0.74 in the combined group and 1.40±0.78 in the control group.
Results:
There were no intra- and postoperative complications. By the end of the follow-up period, a significant decrease in the mean IOP level compared to its preoperative value by 29.4% (7.11±1.43 mm Hg) was determined in the combined group, and 9.8% (2.02±0.29 mm Hg) in the control (P<0.05). At 12 months, the mean number of medications decreased from 1.52±0.74 to 0.64±0.36 in the combined group, and in the control group, on the contrary, the mean number of medications increased from 1.40±0.78 to 1.91±0.70 (P<0.05).
Conclusions:
In the long-term postoperative period after combined treatment (phacoemulsification with YAG-LAT), IOP normalization was achieved in 94.4% of cases, as well as a significant increase in visual acuity of patients. Combined phacoemulsification and YAG-LAT was statistically effective in reducing IOP and/or medication burden in POAG patients. The developed method of treatment is safe, has a minimal risk of complications and can be used for the treatment of patients with initial stages of POAG in combination with complicated cataracts.
Financial Disclosure:
None